4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Reticulospinal Control of Movements

Reticulospinal Control of Movements

Study Description
Brief Summary:

Accurate movement execution is a result of a complex interplay between various muscle groups whose activity is controlled by different areas of the central nervous system. Besides the corticospinal system, the phylogenetically old reticulospinal system is a key motor system controlling different elementary movements including posture, locomotion and reaching across all mammals. In contrast to the extensively investigated corticospinal system, there is only sparse knowledge on the motor physiology of the functionally important reticulospinal system in humans. Reticulospinal motor control can be assessed with the StartReact paradigm which is based on the activation of reticulospinal motor circuitries by startling acoustic stimuli. The StartReact phenomenon is characterized by a shortening in movement reaction time which is mediated by a startle-triggered, early release of a planned motor program by the reticulospinal system. Thus, StartReact is a unique tool to examine reticulospinal involvement on human motor control under physiological and pathological conditions. StartReact assessments will be supplemented by comprehensive 3-D kinematic analysis and muscle activity recordings (i.e. electromyography) to gain quantitative insights into reticulospinal movement control.

The first objective of this clinical study is to gain more insights into the mechanisms underlying StartReact and to advance the knowledge on reticulo-spinal motor physiology regarding different movement tasks (i.e. simple single-joint movements, complex multi-joint movements and bilateral hand movements) in healthy subjects. The findings of these experiments will provide new insights into proximal-distal, flexor-extensor and upper-lower extremity gradients in reticulospinal motor control of healthy subjects. Moreover, the results will expand the StartReact paradigm to complex, functionally more relevant movements (i.e. reaching and stepping tasks requiring endpoint accuracy; co-operative, bilateral hand movements) for which the involvement of the reticulo-spinal system is not yet understood.

The second goal of this project is to use the StartReact paradigm to shed more light onto the role of reticulospinal plasticity in functional recovery of patients with spinal cord injury (SCI). Whereas preclinical findings emphasize a remarkable potential of the reticulospinal system for neuroplastic adaptations underlying functional recovery, there is only little evidence from clinical trials in the field of SCI. First, the study aims at monitoring StartReact effects in hand and leg muscles of patients with acute SCI over a period of 6 months. Simultaneous tracking of StartReact effects and motor recovery will allow to closely relate processes of reticulospinal plasticity to functional recovery in patients with acute SCI. Second, the focus will be on the re-weighting of descending motor control (i.e. cortico- vs. reticulospinal system) in response to SCI and investigate the distinct contributions of the cortico- and reticulospinal system to motor recovery in patients with chronic SCI.

The findings of this project will advance the mechanistic understanding on the motor physiology and neurorestorative capacity of the reticulospinal system in humans. New insights from these projects will hopefully translate into a better exploitation of this important motor system in clinical trials that aim to improve motor recovery in patients with SCI.


Condition or disease Intervention/treatment Phase
Spinal Cord Injuries Healthy Procedure: Startling acoustic stimulus Not Applicable

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 102 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Each participants receives real and control interventions.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Contributions of the Reticulospinal System to Movement Control and Functional Recovery in Patients With Spinal Cord Injury
Estimated Study Start Date : December 1, 2021
Estimated Primary Completion Date : September 30, 2024
Estimated Study Completion Date : September 30, 2024
Arms and Interventions
Arm Intervention/treatment
Experimental: Spinal cord injured subjects Procedure: Startling acoustic stimulus
StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus.

Outcome Measures
Primary Outcome Measures :
  1. EMG analysis (i.e. shortening of movement reaction time of target muscle(s)) during Loud vs. Moderate Acoustic Stimuli (LAS vs. MAS) [ Time Frame: Baseline ]
  2. Change in EMG analysis (i.e. shortening of movement reaction time of target muscle(s)) [ Time Frame: Change in shortening of movement reaction time between baseline and visit 1 (7-14 days). ]
  3. Change in EMG analysis (i.e. shortening of movement reaction time of target muscle(s)) [ Time Frame: Change in shortening of movement reaction time at 3 and 6 months relative to baseline. ]
  4. Intramuscular coherence of paired EMG signals of the tibialis anterior muscle to assess corticospinal drive in the StartReact paradigm. [ Time Frame: Baseline ]
  5. Modulation of EMG reflex responses (as induced by electrical ulnar nerve stimulation) by simultaneous acoustic stimulation with LAS [ Time Frame: Baseline ]
  6. Transcranial magnetic stimulation (TMS) to investigate corticospinal physiology/ integrity. [ Time Frame: Baseline ]

Secondary Outcome Measures :
  1. Analysis of movement patterns of fast vs. slow movements based on 3D kinematics. [ Time Frame: Baseline ]
  2. Endpoint accuracy of fast vs. slow reaching and stepping movements based on a combined Virtual Reality (VR)/ kinematic system. [ Time Frame: Baseline ]
  3. Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP) to measure upper extremity function (only for SCI) [ Time Frame: The outcome is used for 2 sub-projects of this study: one sub-project conducts GRASSP at > 12 months after spinal cord injury, whereas the other sub-project conducts GRASSP at 3 visits (at < 1, 3 and 6 months after spinal cord injury). ]
  4. International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) (only for SCI) [ Time Frame: The outcome is used for 2 sub-projects of this study: one sub-project conducts ISNCSCI at > 12 months after spinal cord injury, whereas the other sub-project conducts ISNCSCI at 3 visits (at < 1, 3 and 6 months after spinal cord injury). ]
  5. 10-meter walk test (only for SCI) [ Time Frame: Baseline ]
  6. 6-minute walk test (only for SCI) [ Time Frame: Baseline ]
  7. Modified Ashworth Scale (MAS) (only for SCI) [ Time Frame: Baseline ]

Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Written informed consent as documented by signature

For SCI patients:

  • ASIA Impairment scale (AIS) A-D
  • Focal damage at cervical (C4-C7; i.e. damage rostral of the spi-nal segments innervating the examined hand and leg muscles) or thoracic (T4-T12; i.e. damage caudal of the spinal segments innervating the m. abductor digiti minimi, but rostral of the spi-nal segments innervating the m. tibialis anterior)
  • Patients with cervical SCI must reveal bilaterally intact ulnar nerves as demonstrated by normal compound motor action potential (cMAP), nerve conduction velocity (NCV) and F-wave latencies in clinical neurography.
  • Patients with thoracic SCI must reveal bilaterally intact tibial and peroneal nerves as demonstrated by normal cMAP, NCV and F-wave latencies

Exclusion Criteria:

  • Women who are pregnant or breast feeding
  • Current neurological problems other than SCI and related impairments
  • Current orthopaedic problems affecting upper and lower extremity movements
  • History of alcohol abuse or the intake of psychotropic drugs
  • History of major cardiac condition (e.g., infarction, insufficiency (NYHA II-IV))
  • History of major pulmonary condition (e.g., chronic obstructive pulmonary disease (GOLD II-IV))
  • Current major depression or psychosis
  • Fever of unknown origin
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Linard Filli, Dr. +41 44 510 72 12 linard.filli@balgrist.ch

Locations
Layout table for location information
Switzerland
Balgrist University Hospital
Zürich, Switzerland, 8008
Contact: Linard Filli, Dr.    +41 44 510 72 12    linard.filli@balgrist.ch   
Principal Investigator: Curt Armin, Prof. Dr.         
Sponsors and Collaborators
University of Zurich
Tracking Information
First Submitted Date  ICMJE May 26, 2021
First Posted Date  ICMJE July 19, 2021
Last Update Posted Date October 6, 2021
Estimated Study Start Date  ICMJE December 1, 2021
Estimated Primary Completion Date September 30, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 16, 2021)
  • EMG analysis (i.e. shortening of movement reaction time of target muscle(s)) during Loud vs. Moderate Acoustic Stimuli (LAS vs. MAS) [ Time Frame: Baseline ]
  • Change in EMG analysis (i.e. shortening of movement reaction time of target muscle(s)) [ Time Frame: Change in shortening of movement reaction time between baseline and visit 1 (7-14 days). ]
  • Change in EMG analysis (i.e. shortening of movement reaction time of target muscle(s)) [ Time Frame: Change in shortening of movement reaction time at 3 and 6 months relative to baseline. ]
  • Intramuscular coherence of paired EMG signals of the tibialis anterior muscle to assess corticospinal drive in the StartReact paradigm. [ Time Frame: Baseline ]
  • Modulation of EMG reflex responses (as induced by electrical ulnar nerve stimulation) by simultaneous acoustic stimulation with LAS [ Time Frame: Baseline ]
  • Transcranial magnetic stimulation (TMS) to investigate corticospinal physiology/ integrity. [ Time Frame: Baseline ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 16, 2021)
  • Analysis of movement patterns of fast vs. slow movements based on 3D kinematics. [ Time Frame: Baseline ]
  • Endpoint accuracy of fast vs. slow reaching and stepping movements based on a combined Virtual Reality (VR)/ kinematic system. [ Time Frame: Baseline ]
  • Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP) to measure upper extremity function (only for SCI) [ Time Frame: The outcome is used for 2 sub-projects of this study: one sub-project conducts GRASSP at > 12 months after spinal cord injury, whereas the other sub-project conducts GRASSP at 3 visits (at < 1, 3 and 6 months after spinal cord injury). ]
  • International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) (only for SCI) [ Time Frame: The outcome is used for 2 sub-projects of this study: one sub-project conducts ISNCSCI at > 12 months after spinal cord injury, whereas the other sub-project conducts ISNCSCI at 3 visits (at < 1, 3 and 6 months after spinal cord injury). ]
  • 10-meter walk test (only for SCI) [ Time Frame: Baseline ]
  • 6-minute walk test (only for SCI) [ Time Frame: Baseline ]
  • Modified Ashworth Scale (MAS) (only for SCI) [ Time Frame: Baseline ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Reticulospinal Control of Movements
Official Title  ICMJE Contributions of the Reticulospinal System to Movement Control and Functional Recovery in Patients With Spinal Cord Injury
Brief Summary

Accurate movement execution is a result of a complex interplay between various muscle groups whose activity is controlled by different areas of the central nervous system. Besides the corticospinal system, the phylogenetically old reticulospinal system is a key motor system controlling different elementary movements including posture, locomotion and reaching across all mammals. In contrast to the extensively investigated corticospinal system, there is only sparse knowledge on the motor physiology of the functionally important reticulospinal system in humans. Reticulospinal motor control can be assessed with the StartReact paradigm which is based on the activation of reticulospinal motor circuitries by startling acoustic stimuli. The StartReact phenomenon is characterized by a shortening in movement reaction time which is mediated by a startle-triggered, early release of a planned motor program by the reticulospinal system. Thus, StartReact is a unique tool to examine reticulospinal involvement on human motor control under physiological and pathological conditions. StartReact assessments will be supplemented by comprehensive 3-D kinematic analysis and muscle activity recordings (i.e. electromyography) to gain quantitative insights into reticulospinal movement control.

The first objective of this clinical study is to gain more insights into the mechanisms underlying StartReact and to advance the knowledge on reticulo-spinal motor physiology regarding different movement tasks (i.e. simple single-joint movements, complex multi-joint movements and bilateral hand movements) in healthy subjects. The findings of these experiments will provide new insights into proximal-distal, flexor-extensor and upper-lower extremity gradients in reticulospinal motor control of healthy subjects. Moreover, the results will expand the StartReact paradigm to complex, functionally more relevant movements (i.e. reaching and stepping tasks requiring endpoint accuracy; co-operative, bilateral hand movements) for which the involvement of the reticulo-spinal system is not yet understood.

The second goal of this project is to use the StartReact paradigm to shed more light onto the role of reticulospinal plasticity in functional recovery of patients with spinal cord injury (SCI). Whereas preclinical findings emphasize a remarkable potential of the reticulospinal system for neuroplastic adaptations underlying functional recovery, there is only little evidence from clinical trials in the field of SCI. First, the study aims at monitoring StartReact effects in hand and leg muscles of patients with acute SCI over a period of 6 months. Simultaneous tracking of StartReact effects and motor recovery will allow to closely relate processes of reticulospinal plasticity to functional recovery in patients with acute SCI. Second, the focus will be on the re-weighting of descending motor control (i.e. cortico- vs. reticulospinal system) in response to SCI and investigate the distinct contributions of the cortico- and reticulospinal system to motor recovery in patients with chronic SCI.

The findings of this project will advance the mechanistic understanding on the motor physiology and neurorestorative capacity of the reticulospinal system in humans. New insights from these projects will hopefully translate into a better exploitation of this important motor system in clinical trials that aim to improve motor recovery in patients with SCI.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Each participants receives real and control interventions.
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE
  • Spinal Cord Injuries
  • Healthy
Intervention  ICMJE Procedure: Startling acoustic stimulus
StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus.
Study Arms  ICMJE Experimental: Spinal cord injured subjects
Intervention: Procedure: Startling acoustic stimulus
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: July 16, 2021)
102
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 30, 2024
Estimated Primary Completion Date September 30, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Written informed consent as documented by signature

For SCI patients:

  • ASIA Impairment scale (AIS) A-D
  • Focal damage at cervical (C4-C7; i.e. damage rostral of the spi-nal segments innervating the examined hand and leg muscles) or thoracic (T4-T12; i.e. damage caudal of the spinal segments innervating the m. abductor digiti minimi, but rostral of the spi-nal segments innervating the m. tibialis anterior)
  • Patients with cervical SCI must reveal bilaterally intact ulnar nerves as demonstrated by normal compound motor action potential (cMAP), nerve conduction velocity (NCV) and F-wave latencies in clinical neurography.
  • Patients with thoracic SCI must reveal bilaterally intact tibial and peroneal nerves as demonstrated by normal cMAP, NCV and F-wave latencies

Exclusion Criteria:

  • Women who are pregnant or breast feeding
  • Current neurological problems other than SCI and related impairments
  • Current orthopaedic problems affecting upper and lower extremity movements
  • History of alcohol abuse or the intake of psychotropic drugs
  • History of major cardiac condition (e.g., infarction, insufficiency (NYHA II-IV))
  • History of major pulmonary condition (e.g., chronic obstructive pulmonary disease (GOLD II-IV))
  • Current major depression or psychosis
  • Fever of unknown origin
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Linard Filli, Dr. +41 44 510 72 12 linard.filli@balgrist.ch
Listed Location Countries  ICMJE Switzerland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04967274
Other Study ID Numbers  ICMJE 2021-00973
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of Zurich
Study Sponsor  ICMJE University of Zurich
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account University of Zurich
Verification Date October 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP